Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).
Marc Peeters
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Kelly Smith Oliner
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Timothy Jay Price
Consultant or Advisory Role - Amgen
Andres Cervantes
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Alberto F. Sobrero
Consultant or Advisory Role - Amgen; Bayer; Merck; Roche; Sanofi
Honoraria - Amgen; Bayer; Celgene; Merck; Roche; Sanofi
Michel Ducreux
Consultant or Advisory Role - Roche
Honoraria - Amgen; Bayer; Biocompatibles; Merck; Pfizer; Roche
Research Funding - Pfizer; Roche
Yevhen Hotko
No relevant relationships to disclose
Thierry Andre
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Emily Chan
Research Funding - Amgen
Florian Lordick
Honoraria - Med Update GmbH
Research Funding - Fresenius Biotech; GlaxoSmithKline; Merck
Cornelis J. A. Punt
Consultant or Advisory Role - Amgen; Roche
Andrew Strickland
No relevant relationships to disclose
Gregory Wilson
Honoraria - Amgen
Other Remuneration - Amgen
Tudor E. Ciuleanu
No relevant relationships to disclose
Laslo Roman
Research Funding - Amgen
Eric Van Cutsem
Research Funding - Amgen
Hua Yu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Andre Scott Jung
Employment or Leadership Position - Amgen
Roger Sidhu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Scott D. Patterson
Employment or Leadership Position - Amgen
Stock Ownership - Amgen